Table 3.
Comparison of the mean values in both groups as regard clinical and laboratory parameters at baseline and after 3 months of follow up.
| Antioxidants/zinc group (A) |
Lactulose group (B) |
p3 value | |||||
|---|---|---|---|---|---|---|---|
| Baseline | 3 months | p1 value | Baseline | 3 months | p2 value | ||
| NCT-A (s) | 67.68 ± 4.86 | 56.80 ± 3.07 | <0.001 | 67.93 ± 4.53 | 64. 3 ± 5.31 | <0.001 | <0.001 |
| DST (points) | 10.11 ± 1.34 | 12.36 ± 0.87 | <0.001 | 10.07 ± 1.51 | 11.58 ± 1.19 | <0.001 | <0.006 |
| BDT (s) | 77.32 ± 3.65 | 68.35 ± 3.9 | <0.001 | 77.78 ± 2.68 | 74.52 ± 4.55 | 0.002 | <0.001 |
| Ammonia (µg⁄dl) | 65.1 ± 26.1 | 50.4 ± 18.3 | <0.001 | 67.8 ± 25.5 | 55.9 ± 16.7 | 0.048 | 0.24 |
| Total bilirubin (mg⁄dl) | 1.39 ± 0.32 | 1.21 ± 0.35 | 0.04 | 1.4 ± 0.42 | 1.29 ± 0.37 | 0.32 | 0.4 |
| Albumin (g⁄dl) | 3.45 ± 0.42 | 3.5 ± 0.42 | 0.81 | 3.5 ± 0.34 | 3.5 ± 0.44 | 0.11 | 0.47 |
| ALT (IU/ml) | 69.6 ± 20.5 | 52.19 ± 12.47 | <0.001 | 68.4 ± 18.2 | 62.2 ± 20.2 | 0.78 | 0.001 |
| AST (IU/ml) | 76.5 ± 22.7 | 53.3 ± 12.5 | <0.001 | 67.56 ± 19.5 | 68.4 ± 20.2 | 0.23 | 0.002 |
| Prothrombin concentration (%) | 70.4 ± 12.1 | 78.3 ± 11.4 | 0.01 | 70.6 ± 12.7 | 71.9 ± 12.4 | 0.71 | 0.045 |
| Zinc (µg⁄dl) | 49.6 ± 11.2 | 75.6 ± 16.8 | <0.001 | 46.9 ± 10.5 | 48.7 ± 9.2 | 0.7416 | < 0.001 |
| Child–Pugh score | 6⁄22⁄3 | 16⁄12⁄3 | 0.024 | 4⁄20⁄3 | 11⁄13⁄3 | 0.09 | 0.07 |
ALT, alanine transaminase; AST, aspartate transaminase; BDT, block design test; DST, digit symbol test; NCT-A, number connection test part A; p1, group A before and after therapy; p2, group B before and after therapy; p3, group A and B after therapy.